Have you forgotten how good these 3 high yields really are?

Harvey Jones says that investors are really spoilt for choice with great income stocks like these on sale at undemanding valuations.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sometimes I wonder whether today’s income investors know how lucky they are. The following three stocks all yield 5% or more, without offering undue risk. So why aren’t they in your portfolio?

Turn up the heat

Winter is coming, which is traditionally good news for British Gas owner Centrica (LSE: CNA). Although that hasn’t been the case in recent years, as a series of mild UK winters have hit usage. Several years of low commodity prices have added to the pain, contributing to three years of negative earnings per share (EPS) growth, although some hope natural resources prices will pick up, with Rio Tinto’s chief executive spotting an “inflection point”, as copper prices bottom and Chinese demand rises. 

Centrica’s share price is down 25% over the past five years, not what you expect from a supposedly defensive utility stock. It has responded like many energy companies, by slashing costs and offloading non-core assets. There are signs of a turnaround, with EPS forecast to rise 7% in 2017. Some investors may have been put off by Centrica’s recent 30% dividend cut but this remains a generous high-yielder, currently paying 5.2%, covered 1.4 times. That is forecast to hit 5.6% at the end of 2017. Trading at 13.5 times earnings it still looks a long-term buy-and-hold for income fans.

Legal matters

Insurance company Legal & General Group (LSE: LGEN) has continued its Brexit fightback, rising almost 30% from its post-referendum trough. It’s been helped by a successful update this week, which showed its retirement division on course to almost double its new business sales in 2016 to £5.4bn, against £2.9bn for 2015. Customer demand for bulk annuities and lifetime mortgages is apparently unaffected by Solvency II regulation, Brexit uncertainty or lower interest rates.

Bulk annuity business is also growing strongly – offsetting slowing individual annuity sales – as is its recently launched lifetime mortgages spin-off, with sales on track to top £500m in 2016. Equity release looks set to be a major growth industry, and L&G is building its position nicely. Despite these promising signs, it trades at just 11.1 times earnings, while yielding a generous 6.1%, covered 1.4 times. EPS growth of 16% this year will slow to 2% in 2017, and Brexit may cause some pain once Article 50 is actually triggered, but L&G is an income seeker’s dream today.

Friends electric

Power giant SSE (LSE: SSE) has trailed the FTSE 100 over five years, growing 20% against 33% for the index as a whole, but most investors buy for its income stream rather than its growth prospects. There have also been concerns on this front, over fears that slowing cash generation could squeeze payouts, although it’s still covered 1.3 times. The yield is certainly holding up, today you get 5.74% from a stock trading at an undemanding 13.2 times earnings.

There’s little sign that SSE will suddenly transform into a growth monster: revenues have bobbed around the £30bn mark for the last five years and forecasts suggest little sign that this is set to change. Instead, dividends have been funded by a disposals programme that is now drawing to a close, as well as debt and share issuance. Management still aims to increase the dividend by RPI, which is currently 1.8%, but SSE needs to generate more cash to meet that pledge. Quibbles aside, SSE looks set to remain an electric dividend stock.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »